Drug transporters and imatinib treatment: implications for clinical practice.
about
Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA AnalysisRole of solute carriers in response to anticancer drugsCurrent management and prognostic features for gastrointestinal stromal tumor (GIST)A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Electrospun Poly(ε-caprolactone) Composite Nanofibers with Controlled Release of Cis-Diamminediiodoplatinum for a Higher Anticancer Activity.Imatinib: a breakthrough of targeted therapy in cancer.Environmental and genetic factors affecting transport of imatinib by OATP1A2Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceInteraction of innovative small molecule drugs used for cancer therapy with drug transporters.Contribution of tumoral and host solute carriers to clinical drug response.Recent advances and novel agents for gastrointestinal stromal tumor (GIST)Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors.Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1.ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib.Uptake carriers and oncology drug safety.Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Controversies in the management of gastrointestinal stromal tumors.Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2.Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin.Identification of a novel fusion gene involving RUNX1 and the antisense strand of SV2B in a BCR-ABL1-positive acute leukemia.Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.
P2860
Q26800005-CEBA7017-6B9A-4343-9A9E-2FBCC1873C45Q27027625-A8E2BBD5-92B9-4B1D-9881-CE62A3D94434Q28391684-3ACA6E54-F3D5-492A-8182-9BD41BC47BC3Q33427392-709A60D6-A10D-4F77-B55D-8ED440347CEFQ33434697-25486A10-E300-4267-98CF-15B081976B14Q33612466-76A11097-F66C-4A40-923A-C4B11210CBE9Q33747261-C0C6D31B-DC2A-4750-9B6A-FD88D8C2C471Q33878471-D4DD5258-C17C-40CB-9655-969F0604A4B4Q33908105-3D6A20CE-17FD-406B-A1BC-1D04D753DC4FQ34046157-CF8EAFB9-D5D3-406C-8000-384181F01318Q34499668-0251E238-CC87-4018-A4DF-6FA76DF95141Q34774289-384D58B4-CC2F-41EB-B84A-ADD9EB36E142Q34774854-A28D5800-C2B2-4D39-828A-DE01AD7D82D7Q35708124-AE3B0577-E56B-4739-8901-5D095F74D6D9Q35946876-032761FB-1B4D-4795-BF9D-329C9245C2B5Q36118178-A25BEF34-2C56-4D53-B918-1898DF6EA23BQ36180074-EEC9C728-C7AB-402A-8155-D5EA0DC91C0CQ36946637-30C50053-9B33-42C2-8E36-33AB7F95A42BQ37598626-5A0CF506-94FF-43B3-9E89-C330E435DDCDQ37633542-D4753F5F-577D-4126-803F-FEC480BDAEDAQ37652283-C8A9046B-3DCA-4242-AA41-170543BCBB8AQ37663396-5C503FB9-A449-465C-BE70-B5336F5E38F7Q37729245-DBF9308A-A565-4979-9953-FE063447D1C4Q37889961-55D0DC12-520E-41F7-8248-40C4489E4890Q38071700-05C17A7D-A681-46FD-95C9-30217058ACE0Q38112821-8F84DC3F-61E5-4B39-A529-C4AA6A76944EQ38183877-AADB3156-BE97-4C61-AF18-95F036937BA2Q38199797-B37940B1-0DD5-4AF7-8797-420E7F3E62AFQ38843265-0FC00191-1BD7-42DF-8744-DD2A7C2D1BFEQ38902116-FB86360E-5E31-4B64-8D8B-6324B8CE629EQ39121828-9B09F285-3652-492B-9C92-30D050AC8AA3Q39293014-B4335454-89B9-4DD3-94BF-7E3924027FDDQ40003126-6E305A98-CE00-4011-85F6-0B9157D8F014Q40721053-9C3D7FD7-99D6-4B3D-8591-18D8F61DC4DFQ41612371-F2B7D46B-96AC-4F89-B93E-129CC9B18D60Q41842515-B5024E35-2A1A-420A-8DA5-6E96C4213694Q42052611-0D77A4F3-E3FF-4140-B9D7-90E7AB22FCBFQ42623221-33A2307B-C58C-4A4B-BC05-A12BFF0296EDQ44529953-B14DB5F3-4B25-4855-9B2B-48C52B78E0CBQ46431899-CF299D7B-9E82-4EBA-81EF-271DF1C4A169
P2860
Drug transporters and imatinib treatment: implications for clinical practice.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Drug transporters and imatinib treatment: implications for clinical practice.
@ast
Drug transporters and imatinib treatment: implications for clinical practice.
@en
type
label
Drug transporters and imatinib treatment: implications for clinical practice.
@ast
Drug transporters and imatinib treatment: implications for clinical practice.
@en
prefLabel
Drug transporters and imatinib treatment: implications for clinical practice.
@ast
Drug transporters and imatinib treatment: implications for clinical practice.
@en
P2093
P1476
Drug transporters and imatinib treatment: implications for clinical practice.
@en
P2093
Erik A C Wiemer
Gaia Schiavon
Herman Burger
Jaap Verweij
Karel Eechoute
Ron H J Mathijssen
Ryan M Franke
Walter J Loos
P304
P356
10.1158/1078-0432.CCR-10-2250
P407
P577
2010-12-16T00:00:00Z